GlassScriptPhysician profile
Baaz Mishiev
NPI 1245472869
$9,338.99
in general payments reported to CMS, 2019-2025
31 companies · $1,625 in 2025
The $1,625 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $302 · 2021: $193 · 2022: $1,845 · 2023: $3,358 · 2024: $1,305 · 2025: $1,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,978 · Consulting Fee: $1,680 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,978.45 |
| Consulting Fee | $1,680.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $630.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation | $3,570.00 | 2022-2023 | Evis Exera III Video System Center |
| Abbvie INC. | $1,127.83 | 2019-2025 | |
| Genzyme Corporation | $624.98 | 2022-2025 | |
| Qol Medical, LLC | $561.89 | 2022-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $530.02 | 2020-2025 | Tremfya, Stelara, Simponi |
| Celgene Corporation | $517.43 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $490.87 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Intercept Pharmaceuticals, INC. | $292.66 | 2020-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $213.91 | 2019-2025 | Gattex, Eohilia |
| Gilead Sciences, INC. | $204.34 | 2019-2025 | |
| Braintree Laboratories, INC. | $201.42 | 2019-2025 | Sutab, Suflave |
| Ardelyx, INC. | $167.35 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $123.71 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $114.92 | 2024-2025 | Rebyota |
| Ironwood Pharmaceuticals, INC | $80.76 | 2019-2023 | Linzess |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $73.29 | 2024-2025 | Zenpep |
| Daiichi Sankyo INC. | $61.84 | 2019-2020 | |
| Madrigal Pharmaceuticals | $55.03 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $50.45 | 2021-2024 | Dificid |
| Allergan, INC. | $33.45 | 2019 | |
| Shionogi INC | $33.06 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $33.04 | 2025 | Iqirvo |
| Novo Nordisk INC | $31.19 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $27.91 | 2024 | Dupixent |
| Janssen Scientific Affairs, LLC | $22.08 | 2025 | Tremfya |
| Cashflow Solutions, LLC | $20.67 | 2025 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Ucb, INC. | $17.84 | 2019 | |
| Alfasigma USA, INC. | $17.40 | 2020 | |
| Celltrion USA INC. | $16.99 | 2024 | Vegzelma |
| Redhill Biopharma INC. | $14.64 | 2021 | |
| Phathom Pharmaceuticals, INC. | $8.02 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baaz Mishiev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.